This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
UPLs present opportunities for payers and financial challenges for pharmacies, leaving manufacturers with difficult choices. Lower per-script reimbursement to...
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.
